Pharmaceutical Benefits Advisory Committee (PBAC) Meeting Outcomes
MGBase data has been influential in developing a Health Technology Assessment framework for the reimbursement of four new MG treatments in Australia, with important information able to be provided on current use of quick onset therapies in MG such as IVIG as a comparator in the PICO (population, intervention, comparator, outcome) analysis.
Summary
The Pharmaceutical Benefits Advisory Committee of Australia took into account this data along with input from clinicians and patient groups in recommending reimbursement for efgartigimod, ravulizumab, rozanolixizumab and zilucoplan for reimbursement
